Stockscreener 앱 받기
93.58
0.50%
-0.415
전일 마감가:
$93.99
열려 있는:
$93.49
하루 거래량:
251.98K
Relative Volume:
0.22
시가총액:
$11.42B
수익:
$2.72B
순이익/손실:
$254.30M
주가수익비율:
45.28
EPS:
2.0665
순현금흐름:
$564.37M
1주 성능:
-1.62%
1개월 성능:
-1.39%
6개월 성능:
-25.75%
1년 성능:
-7.05%
1일 변동 폭
$92.58
$94.27
1주일 범위
$91.18
$96.50
52주 변동 폭
$88.53
$129.50
퍼킨엘머 Stock (RVTY) Company Profile
명칭
Revvity Inc
전화
781-663-6900
주소
77 4TH AVENUE, WALTHAM
RVTY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
93.55 | 11.42B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
423.32 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
199.02 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
476.67 | 35.17B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
109.06 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.54 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
퍼킨엘머 Stock (RVTY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-01 | 업그레이드 | UBS | Neutral → Buy |
| 2025-01-10 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-15 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-07-08 | 개시 | Leerink Partners | Outperform |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-19 | 개시 | Raymond James | Outperform |
| 2023-05-23 | 재개 | Goldman | Buy |
모두보기
퍼킨엘머 주식(RVTY)의 최신 뉴스
UBS Upgrades Revvity (BMV:RVTY) - Nasdaq
UBS Upgrades Revvity (BIT:1RVTY) - Nasdaq
UBS lifts Revvity stock rating to Buy, cuts price target to $115 - Investing.com Australia
UBS Upgrades Revvity (LSE:0KHE) - Nasdaq
UBS Upgrades Revvity (RVTY) - Nasdaq
UBS Boosts Revvity (RVTY) Rating to Buy Amid Growth Prospects | - GuruFocus
UBS lifts Revvity stock rating to Buy, cuts price target to $115 By Investing.com - Investing.com South Africa
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
UBS Upgrades Revvity to Buy from Neutral, Cuts Price Target to $115 From $145 - marketscreener.com
Revvity to Present at Upcoming Investor Conferences | RVTY Stock News - GuruFocus
KeyBanc Adjusts Revvity's Price Target to $135 From $145 - marketscreener.com
Revvity CEO and CFO to Share Strategic Vision at BofA and Goldman Sachs Healthcare Conferences - Stock Titan
Revvity Reports Strong Q1 2025 Financial Results - TipRanks
Revvity reaffirms 2025 guidance with $4.90-$5 EPS target amid robust software growth - MSN
Stifel maintains Revvity stock Hold rating, $120 target By Investing.com - Investing.com Canada
Biotech Firm Revvity Reports Better-Than-Expected Earnings - MSN
Stifel maintains Revvity stock Hold rating, $120 target - Investing.com
Revvity (RVTY) Price Target Adjusted by Baird After Q1 Results | - GuruFocus
Revvity, Inc. (NYSE:RVTY) Q1 2025 Earnings Call Transcript - Insider Monkey
Revvity Exceeds Expectations: Strong Biotech Demand Fuels GrowthNews and Statistics - IndexBox
Revvity First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Raymond James Adjusts Price Target on Revvity to $120 From $145, Maintains Outperform Rating - marketscreener.com
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... - Yahoo Finance
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... By GuruFocus - Investing.com Canada
Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing - GuruFocus
Jefferies Updates Revvity (RVTY) Price Target Amid Market Develo - GuruFocus
Revvity’s Earnings Call: Balanced Growth Amid Challenges - TipRanks
Revvity (RVTY) Price Target Reduced by Citi to $135, Buy Rating Maintained | RVTY Stock News - GuruFocus
Jefferies Cuts Price Target on Revvity to $106 From $130 - marketscreener.com
Earnings call transcript: Revvity beats Q1 2025 earnings expectations - Investing.com
Earnings call transcript: Revvity beats Q1 2025 earnings expectations By Investing.com - Investing.com India
Revvity: Q1 Earnings Snapshot - The Wilton Bulletin
Revvity (RVTY) Exceeds Q1 Expectations with Robust Diagnostics G - GuruFocus
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up - Yahoo Finance
Revvity Q1 2025 slides: 4% organic growth driven by strong Diagnostics performance - Investing.com
Evercore ISI Adjusts Price Target on Revvity to $116 From $125 - marketscreener.com
Revvity's Steady Demand Lifts Q1 Results Above Expectations - Finimize
Earnings Summary: Revvity (RVTY) reports higher revenue and earnings for Q1 2025 - AlphaStreet
Revvity Q1 Earnings Surpass Street Estimates, Investors Cheer 2025 Revised Revenue Guidance - MSN
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Benzinga
Revvity (RVTY) Surpasses Q1 Estimates and Updates 2025 Outlook - GuruFocus
Revvity, Inc. (RVTY) Implements Majority Voting Standard Followi - GuruFocus
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Revvity beats Q1 estimates, shares jump 4% - Investing.com
Revvity Announces Financial Results for the First Quarter of 202 - GuruFocus
Revvity beats Q1 estimates, shares jump 4% By Investing.com - Investing.com Nigeria
Revvity (RVTY) Exceeds Q1 Revenue Expectations with Strong Perfo - GuruFocus
REVVITY Earnings Results: $RVTY Reports Quarterly Earnings - Nasdaq
퍼킨엘머 (RVTY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
0.21%
자본화:
|
볼륨(24시간):